ELVN
Enliven Therapeutics Inc.
44.80$
-0.9%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -100.0% | – | – | – | -100.0% | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | +0.0% | -4.0% | +4.2% | +0.0% | +1,880.0% | -79.0% | – | – | +10.4% | +6.8% | -2.5% | +2.6% | +0.0% | +1.3% | +97.5% | -53.2% | +9.5% | – | – | -69.6% | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -121.8% | – | – | – | -146.8% | – | – | – | – | – | – | |
| – | +22.6% | +17.8% | +15.6% | -2.5% | +35.8% | +21.1% | -6.0% | -20.6% | +41.6% | +3.2% | -34.0% | +2.8% | +12.4% | -1.4% | +4.7% | +44.9% | +27.8% | +29.1% | -8.7% | +11.5% | -5.7% | +12.9% | -2.5% | +20.1% | -13.7% | -15.2% | +16.6% | -2.6% | +40.2% | – | |
| – | +87.9% | +46.2% | -11.5% | +1.2% | +56.1% | +21.7% | -12.5% | +22.2% | -2.2% | +5.4% | -53.1% | +5.7% | -33.4% | +187.8% | -36.7% | +130.8% | -19.5% | -8.5% | +44.3% | +24.7% | -4.0% | +0.6% | +6.2% | +10.1% | +4.3% | -3.1% | +89.8% | -45.3% | +15.1% | – | |
| – | +32.5% | +23.8% | +8.7% | -1.8% | +40.1% | +21.3% | -7.6% | -11.2% | +28.2% | +3.7% | -38.4% | +3.4% | +3.9% | +21.3% | -7.1% | +61.5% | +22.6% | +20.4% | -6.3% | +14.3% | -5.3% | +10.0% | -0.6% | +17.8% | -9.8% | -12.2% | +36.4% | -18.7% | +33.7% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | +420.0% | +41.0% | +120.0% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | +118.4% | -10.4% | -41.2% | -28.5% | -27.6% | -54.9% | -28.1% | -65.2% | +50.0% | -33.3% | +75.0% | -3,264.3% | – | -63.6% | -2,025.0% | – | – | – | -99.3% | +549.4% | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.